BioArctic AB Series B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
Market Cap & Net Worth: BioArctic AB Series B (0RV2)
BioArctic AB Series B (LSE:0RV2) has a market capitalization of $272.67K (Skr3.06 Million) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #8559 globally and #218 in its home market, demonstrating a 7.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioArctic AB Series B's stock price Skr320.80 by its total outstanding shares 9535 (9.54K).
BioArctic AB Series B Market Cap History: 2017 to 2026
BioArctic AB Series B's market capitalization history from 2017 to 2026. Data shows growth from $21.84K to $272.67K (36.42% CAGR).
BioArctic AB Series B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioArctic AB Series B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
BioArctic AB Series B's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $21.84K | $140.71 Million | $15.16 Million | 0.00x | 0.00x |
| 2018 | $22.94K | $713.97 Million | $381.60 Million | 0.00x | 0.00x |
| 2019 | $79.92K | $281.77 Million | $88.47 Million | 0.00x | 0.00x |
| 2020 | $80.87K | $62.35 Million | -$68.52 Million | 0.00x | N/A |
| 2021 | $100.55K | $23.15 Million | -$119.79 Million | 0.00x | N/A |
Competitor Companies of 0RV2 by Market Capitalization
Companies near BioArctic AB Series B in the global market cap rankings as of March 18, 2026.
Key companies related to BioArctic AB Series B by market ranking:
- Dalata Hotel Group plc (OTCGREY:DLTTF): Ranked #8550 globally with a market cap of $735.84 Million USD.
- XD Inc (PINK:XDNCF): Ranked #8551 globally with a market cap of $735.71 Million USD.
- CGN Mining Company Limited (PINK:CGNMF): Ranked #8560 globally with a market cap of $733.90 Million USD.
- Baosheng (SHG:600973): Ranked #8561 globally with a market cap of $733.82 Million USD ( CN¥5.38 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8550 | Dalata Hotel Group plc | OTCGREY:DLTTF | $735.84 Million | $4.88 |
| #8551 | XD Inc | PINK:XDNCF | $735.71 Million | $2.70 |
| #8560 | CGN Mining Company Limited | PINK:CGNMF | $733.90 Million | $0.22 |
| #8561 | Baosheng | SHG:600973 | $733.82 Million | CN¥7.33 |
BioArctic AB Series B Historical Marketcap From 2017 to 2026
Between 2017 and today, BioArctic AB Series B's market cap moved from $21.84K to $ 272.67K, with a yearly change of 36.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr272.67K | +2.56% |
| 2025 | Skr265.87K | +55.74% |
| 2024 | Skr170.71K | -26.08% |
| 2023 | Skr230.93K | -2.58% |
| 2022 | Skr237.05K | +135.76% |
| 2021 | Skr100.55K | +24.33% |
| 2020 | Skr80.87K | +1.20% |
| 2019 | Skr79.92K | +248.31% |
| 2018 | Skr22.94K | +5.06% |
| 2017 | Skr21.84K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BioArctic AB Series B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $272.67K USD |
| MoneyControl | $272.67K USD |
| MarketWatch | $272.67K USD |
| marketcap.company | $272.67K USD |
| Reuters | $272.67K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.